Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study
Fiche du document
8 septembre 2020
- ISIDORE Id: 10670/1.bae2e1...
- hal: hal-03585220
- doi: 10.2147/CIA.S262209
- PUBMED: 32982194
- PUBMEDCENTRAL: PMC7489933
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.2147/CIA.S262209
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32982194
info:eu-repo/semantics/OpenAccess
Sujets proches
TherapyCiter ce document
Anne-Laure Couderc et al., « Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study », HAL SHS (Sciences de l’Homme et de la Société), ID : 10.2147/CIA.S262209
Métriques
Partage / Export
Résumé
BackgroundPolymorbidity induces polypharmacy in older patients may lead to potential drug–drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment.MethodsChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment.ResultsOne hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities – irrespective of grade and type – than patients who received standard treatment (p
